Condition
Pituitary gonadotroph testing
4 compounds were checked against pituitary gonadotroph testing. 1 earned a graded row; the rest are named below.
Last updated
Compounds with a graded row
Ordered by rung, strongest first. The rung rates the study design; the chip beside it says what the study measured. Both are needed.
-
Gonadorelin
human observational Direct outcome Not approved for this condition
- Who was studied
- girls with early pubertal signs, n=263 (314 diagnostic tests) plus 270 monitoring tests during leuprolide treatment, mean age 7.9 years; intravenous gonadorelin acetate with LH and FSH sampled to 90 minutes
This is a diagnostic-agent use, not a treatment: a single intravenous dose of gonadorelin stimulates the pituitary gonadotrophs and the LH response is read as the result. In this cohort a 40-minute LH sample at a 5 IU/L cut-off identified central precocious puberty with 98% sensitivity and 100% specificity against the full sampled test. The former US human product (Factrel) carried exactly this diagnostic indication — evaluating the functional capacity of the anterior pituitary gonadotropes — but was withdrawn, and no human gonadorelin product is currently FDA-approved; the Factrel name on DailyMed today is a veterinary product.
Source PubMed Central 1 primary source read for this row
Recorded absences
2 compounds are listed here without a rung. Each row exists to mark a distinction a reader would otherwise draw wrongly, and each says what is missing rather than leaving the compound off the page.
-
CRH (Corticotropin-Releasing Hormone)
No rung — nothing on file to grade Not approved for this condition
Wrong cell type. CRH stimulates corticotrophs and is read out as ACTH and cortisol; the gonadotroph test uses GnRH or gonadorelin and is read out as LH and FSH. CRH has no place in gonadotroph testing and earns no row here. The corpus has no corticotroph equivalent of this condition, which is where CRH's only licensed use would sit: corticorelin ovine triflutate is approved in the United States for distinguishing pituitary from ectopic ACTH production in ACTH-dependent Cushing's syndrome, and a Cleveland Clinic series of 65 patients with Cushing's disease and 42 in whom it was excluded found the dexamethasone-CRH test detected 5 cases (7.7%) that low-dose dexamethasone alone missed, at 100% sensitivity and 93% specificity (https://pubmed.ncbi.nlm.nih.gov/36917416/). That is a diagnostic-accuracy finding with no treatment outcome, and it has nowhere to go until the condition exists.
-
GHRH (Growth Hormone-Releasing Hormone)
No rung — nothing on file to grade Not approved for this condition
GHRH is a diagnostic stimulus for the somatotroph, not the gonadotroph. Gonadotroph testing uses gonadorelin, so the condition does not apply to this compound even though GHRH has a long diagnostic record of its own.
Checked, and nothing recorded
1 compound was checked against pituitary gonadotroph testing and produced no gradeable row.
A compound is here because someone looked and the sources did not support a row — not because nobody looked. Under the rubric, uncertainty resolves to no row, and a row resting on a vendor page or a clinic blog is worse than no row at all.
What this page does not say
It reports what was measured, in whom, and how directly. It does not say what to take or at what dose, and a row here is a record of a study rather than a reason to use anything. Every rung links to the rubric that assigned it.